Paul R. Sanberg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Paul R. Sanberg has a total of 99 co-authors. Here are the top co-authors by number of shared publications:
- Cesario Venturina Borlongan
University of South Florida
13 shared publications - David J. Eve
Center of Excellence for Aging and Brain Repair, Department of Neurosurgery and Brain Repair, University of South Florida Morsani College of Medicine , Tampa, FL , USA
8 shared publications David J. Eve
University of South Florida
6 shared publications- Svitlana Garbuzova-Davis
Center of Excellence for Aging & Brain Repair, Morsani College of Medicine, University of South Florida, 12901 Bruce B. Downs Blvd., MDC 78, Tampa, FL 33612, USA
6 shared publications Alison E. Willing
Center of Excellence for Aging & Brain Repair, Department of Neurosurgery and Brain Repair, University of South Florida, Tampa, FL, USA
5 shared publications- Paula C. Bickford
Department of Molecular Pharmacology and Physiology, University of South Florida Morsani College of Medicine, Tampa, FL 33612, USA
5 shared publications
Latest Publications
- 29 August 2019
- Published by Taylor & Francis in Regenerative Medicine
- Vol. 14 (9) , 811-813
A ‘Stroke’ of Genius: Celebrating the 20-Year Anniversary of the Bernard Sanberg Memorial Award for Brain Repair
- 29 August 2019
- Published by Taylor & Francis in Regenerative Medicine
- Vol. 14 (9) , 811-813
A ‘Stroke’ of Genius: Celebrating the 20-Year Anniversary of the Bernard Sanberg Memorial Award for Brain Repair
- Open Access
- 11 June 2019
- Published by SAGE Publications in Cell Transplantation
- Vol. 28 (9-10) , 1329-1332
A Hallmark Clinical Study of Cord Blood Therapy in Adults with Ischemic Stroke
The therapeutic application of human umbilical cord blood cells has been an area of great interest for at least the last 25 years. Currently, cord blood cells are approved for reconstitution of the bone marrow following myeloablation in both young and old patients with myeloid malignancies and other blood cancers. Translational studies investigating alternative uses of cord blood have also shown that these cells not only stimulate neurogenesis in the aged brain but are also potentially therapeutic in the treatment of adult neurodegenerative disorders including amyotrophic lateral sclerosis, Alzheimer’s disease, ischemic stroke, traumatic brain injury, and Parkinson’s disease. Recent advances in the clinical application of cord blood cells by Dr. Joanne Kurtzberg and colleagues have found that non-HLA matched allogeneic banked cord blood units in immunocompetent patients with ischemic stroke are safe and well tolerated. Although the exact mechanism(s) of action that provide the beneficial effects observed from a cord blood cell-based therapy are currently unknown, several studies using models of neurodegenerative disease have shown these cells are immune-modulatory and anti-inflammatory. Thus, any future clinical studies investigating the efficacy of this cord blood cell therapeutic would strongly benefit from the inclusion of methodologies to determine changes in both markers of inflammation and the response of immune tissues, such as the spleen, in subjects receiving cell infusion.
- 11 June 2019
- Published by SAGE Publications in Cell Transplantation
- Vol. 28 (9-10) , 1329-1332
Open AccessA Hallmark Clinical Study of Cord Blood Therapy in Adults with Ischemic Stroke
The therapeutic application of human umbilical cord blood cells has been an area of great interest for at least the last 25 years. Currently, cord blood cells are approved for reconstitution of the bone marrow following myeloablation in both young and old patients with myeloid malignancies and other blood cancers. Translational studies investigating alternative uses of cord blood have also shown that these cells not only stimulate neurogenesis in the aged brain but are also potentially therapeutic in the treatment of adult neurodegenerative disorders including amyotrophic lateral sclerosis, Alzheimer’s disease, ischemic stroke, traumatic brain injury, and Parkinson’s disease. Recent advances in the clinical application of cord blood cells by Dr. Joanne Kurtzberg and colleagues have found that non-HLA matched allogeneic banked cord blood units in immunocompetent patients with ischemic stroke are safe and well tolerated. Although the exact mechanism(s) of action that provide the beneficial effects observed from a cord blood cell-based therapy are currently unknown, several studies using models of neurodegenerative disease have shown these cells are immune-modulatory and anti-inflammatory. Thus, any future clinical studies investigating the efficacy of this cord blood cell therapeutic would strongly benefit from the inclusion of methodologies to determine changes in both markers of inflammation and the response of immune tissues, such as the spleen, in subjects receiving cell infusion.
- Open Access
- 1 May 2017
- Published by SAGE Publications in Cell Medicine
- Vol. 9 (3) , 67-71
Article Commentary: Regenerative Rehabilitation: An Innovative and Multifactorial Approach to Recovery from Stroke and Brain Injury
There is currently a dearth of treatment options for stroke or traumatic brain injury that can restore cognitive and motor function. Regenerative and translational medicine have ushered forth promising new methods for mediating recovery in the central nervous system, the most salient of which are rehabilitation and stem cell therapies that, when combined, result in more pronounced recovery than one approach alone.
- 1 May 2017
- Published by SAGE Publications in Cell Medicine
- Vol. 9 (3) , 67-71
Open AccessArticle Commentary: Regenerative Rehabilitation: An Innovative and Multifactorial Approach to Recovery from Stroke and Brain Injury
There is currently a dearth of treatment options for stroke or traumatic brain injury that can restore cognitive and motor function. Regenerative and translational medicine have ushered forth promising new methods for mediating recovery in the central nervous system, the most salient of which are rehabilitation and stem cell therapies that, when combined, result in more pronounced recovery than one approach alone.
- Open Access
- 1 April 2016
- Published by SAGE Publications in Cell Transplantation
- Vol. 25 (4) , 617
Cell Transplantation: Science at the Highest Level
- 1 April 2016
- Published by SAGE Publications in Cell Transplantation
- Vol. 25 (4) , 617
Open AccessCell Transplantation: Science at the Highest Level
- 2 July 2015
- Published by Bentham Science Publishers Ltd. in Recent Patents on Regenerative Medicine
- Vol. 5 (1) , 10-19
Recent Patents in Cell Therapy for Amyotrophic Lateral Sclerosis
Abstract: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by progressive motor neuron degeneration in the brain and spinal cord. Reliable treatment options for this disease are limited due to complexity and multifactorial causes of motor neuron damage. Cell therapy might be a promising treatment for ALS. Numerous preclinical studies have validated the feasibility of cell therapy using various cell types and routes of administration. These cell therapy approaches largely take one of two distinct therapeutic strategies: neuroprotection or motor neuron replacement. Despite some promising results, the success of cell therapy in ALS might rely on a combinative strategy that exploits the benefits of both neuronal cell protection and replacement. Although, ongoing clinical trials provide promising results in cell therapy for treatment of ALS patients, some challenges still facing potential cell therapy development. In this review, current cell products and patent technology related to cell therapeutic strategies are discussed. A detailed discussion of this topic might offer vital insight into the future and viability of cell therapy for ALS.
- 2 July 2015
- Published by Bentham Science Publishers Ltd. in Recent Patents on Regenerative Medicine
- Vol. 5 (1) , 10-19
Recent Patents in Cell Therapy for Amyotrophic Lateral Sclerosis
Abstract: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by progressive motor neuron degeneration in the brain and spinal cord. Reliable treatment options for this disease are limited due to complexity and multifactorial causes of motor neuron damage. Cell therapy might be a promising treatment for ALS. Numerous preclinical studies have validated the feasibility of cell therapy using various cell types and routes of administration. These cell therapy approaches largely take one of two distinct therapeutic strategies: neuroprotection or motor neuron replacement. Despite some promising results, the success of cell therapy in ALS might rely on a combinative strategy that exploits the benefits of both neuronal cell protection and replacement. Although, ongoing clinical trials provide promising results in cell therapy for treatment of ALS patients, some challenges still facing potential cell therapy development. In this review, current cell products and patent technology related to cell therapeutic strategies are discussed. A detailed discussion of this topic might offer vital insight into the future and viability of cell therapy for ALS.
- Open Access
- 1 June 2015
- Published by SAGE Publications in Cell Transplantation
- Vol. 24 (6) , 955-970
Long-Term and Sustained Therapeutic Results of a Specific Promonocyte Cell Formulation in Refractory Angina: ReACT®(Refractory Angina Cell Therapy) Clinical Update and Cost-Effective Analysis
Mononuclear stem cells have been studied for their potential in myocardial ischemia. In our previous published article, ReACT®phase I/II clinical trial, our results suggest that a certain cell population, promonocytes, directly correlated with the perceived angiogenesis in refractory angina patients. This study is ReACT's clinical update, assessing long-term sustained efficacy. The ReACT phase IIA/B noncontrolled, open-label, clinical trial enrolled 14 patients with refractory angina and viable ischemic myocardium, without ventricular dysfunction, who were not suitable for myocardial revascularization. The procedure consisted of direct myocardial injection of a specific mononuclear cell formulation, with a certain percentage of promonocytes, in a single series of multiple injections (24—90; 0.2 ml each) into specific areas of the left ventricle. Primary endpoints were Canadian Cardiovascular Society Angina Classification (CCSAC) improvement at the 12-month follow-up and ischemic area reduction (scintigraphic analysis) at the 12-month follow-up, in correlation with ReACT's formulation. A recovery index (for patients with more than 1 year follow-up) was created to evaluate CCSAC over time, until April 2011. Almost all patients presented progressive improvement in CCSAC beginning 3 months ( p = 0.002) postprocedure, which was sustained at the 12-month follow-up ( p = 0.002), as well as objective myocardium ischemic area reduction at 6 months (decrease of 15%, p < 0.024) and 12 months (decrease of 100%, p < 0.004) The recovery index ( n = 10) showed that the patients were graded less than CCSAC 4 for 73.9 ± 24.2% over a median follow-up time of 46.8 months. After characterization, ReACT's promonocyte concentration suggested a positive correlation with CCSAC improvement ( r = −0.575, p = 0.082). Quality of life (SF-36 questionnaire) improved significantly in almost all domains. Cost-effectiveness analysis showed decrease in angina-related direct costs. Refractory angina patients presented a sustained long-term improvement in CCSAC and myocardium ischemic areas after the procedure. The long-term follow-up and strong improvement in quality of life reinforce effectiveness. Promonocytes may play a key role in myocardial neoangiogenesis. ReACT dramatically decreased direct costs.
- 1 June 2015
- Published by SAGE Publications in Cell Transplantation
- Vol. 24 (6) , 955-970
Open AccessLong-Term and Sustained Therapeutic Results of a Specific Promonocyte Cell Formulation in Refractory Angina: ReACT®(Refractory Angina Cell Therapy) Clinical Update and Cost-Effective Analysis
Mononuclear stem cells have been studied for their potential in myocardial ischemia. In our previous published article, ReACT®phase I/II clinical trial, our results suggest that a certain cell population, promonocytes, directly correlated with the perceived angiogenesis in refractory angina patients. This study is ReACT's clinical update, assessing long-term sustained efficacy. The ReACT phase IIA/B noncontrolled, open-label, clinical trial enrolled 14 patients with refractory angina and viable ischemic myocardium, without ventricular dysfunction, who were not suitable for myocardial revascularization. The procedure consisted of direct myocardial injection of a specific mononuclear cell formulation, with a certain percentage of promonocytes, in a single series of multiple injections (24—90; 0.2 ml each) into specific areas of the left ventricle. Primary endpoints were Canadian Cardiovascular Society Angina Classification (CCSAC) improvement at the 12-month follow-up and ischemic area reduction (scintigraphic analysis) at the 12-month follow-up, in correlation with ReACT's formulation. A recovery index (for patients with more than 1 year follow-up) was created to evaluate CCSAC over time, until April 2011. Almost all patients presented progressive improvement in CCSAC beginning 3 months ( p = 0.002) postprocedure, which was sustained at the 12-month follow-up ( p = 0.002), as well as objective myocardium ischemic area reduction at 6 months (decrease of 15%, p < 0.024) and 12 months (decrease of 100%, p < 0.004) The recovery index ( n = 10) showed that the patients were graded less than CCSAC 4 for 73.9 ± 24.2% over a median follow-up time of 46.8 months. After characterization, ReACT's promonocyte concentration suggested a positive correlation with CCSAC improvement ( r = −0.575, p = 0.082). Quality of life (SF-36 questionnaire) improved significantly in almost all domains. Cost-effectiveness analysis showed decrease in angina-related direct costs. Refractory angina patients presented a sustained long-term improvement in CCSAC and myocardium ischemic areas after the procedure. The long-term follow-up and strong improvement in quality of life reinforce effectiveness. Promonocytes may play a key role in myocardial neoangiogenesis. ReACT dramatically decreased direct costs.
- 30 September 2014
- Published by Springer Nature
- p. 45-53
Menstrual Blood Transplantation Therapy for Stroke and Other Neurological Disorders
- 30 September 2014
- Published by Springer Nature
- p. 45-53
Menstrual Blood Transplantation Therapy for Stroke and Other Neurological Disorders
- 19 July 2014
- Published by Springer Nature
- p. 269-287
Umbilical Cord Blood Cells in the Repair of Central Nervous System Diseases
- 19 July 2014
- Published by Springer Nature
- p. 269-287
Umbilical Cord Blood Cells in the Repair of Central Nervous System Diseases
- 1 June 2014
- Vol. 21 (6) , 243-249
Delayed Umbilical Cord Blood Clamping: First Line of Defense Against Neonatal and Age-Related Disorders
The aging body is unable to maintain homeostasis in cell genesis and function. Stem cell-based regenerative medicine may reverse aging and treat age-related disorders. This perspective article discusses the therapeutic effects of stem cell transplantation on neonatal diseases, which may have long-lasting benefits affecting even the aging process. In particular, the article highlights the potential of the earliest transfer of stem cells between a mother and fetus via the umbilical cord during child birth and how this process may modify the clinical practice of umbilical cord clamping. While such umbilical cord clamping is routinely performed in an expeditious manner after birth for stem cell banking, the present article advances the concept that a delay in clamping the umbilical cord may actually allow more stem cells to be delivered from the mother to the fetus. The authors’ overarching hypothesis is that early umbilical cord clamping results in an artificial loss of stem cells at birth and increases the infant’s susceptibility to both neonatal and age-related diseases, while delaying umbilical cord clamping is perhaps the most effective and non-invasive way to transplant stem cells in order to treat these diseases.
- 1 June 2014
- Vol. 21 (6) , 243-249
Delayed Umbilical Cord Blood Clamping: First Line of Defense Against Neonatal and Age-Related Disorders
The aging body is unable to maintain homeostasis in cell genesis and function. Stem cell-based regenerative medicine may reverse aging and treat age-related disorders. This perspective article discusses the therapeutic effects of stem cell transplantation on neonatal diseases, which may have long-lasting benefits affecting even the aging process. In particular, the article highlights the potential of the earliest transfer of stem cells between a mother and fetus via the umbilical cord during child birth and how this process may modify the clinical practice of umbilical cord clamping. While such umbilical cord clamping is routinely performed in an expeditious manner after birth for stem cell banking, the present article advances the concept that a delay in clamping the umbilical cord may actually allow more stem cells to be delivered from the mother to the fetus. The authors’ overarching hypothesis is that early umbilical cord clamping results in an artificial loss of stem cells at birth and increases the infant’s susceptibility to both neonatal and age-related diseases, while delaying umbilical cord clamping is perhaps the most effective and non-invasive way to transplant stem cells in order to treat these diseases.
- Open Access
- 9 January 2014
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 15 (1) , 895-904
Luteolin Reduces Alzheimer’s Disease Pathologies Induced by Traumatic Brain Injury
Traumatic brain injury (TBI) occurs in response to an acute insult to the head and is recognized as a major risk factor for Alzheimer’s disease (AD). Indeed, recent studies have suggested a pathological overlap between TBI and AD, with both conditions exhibiting amyloid-beta (Aβ) deposits, tauopathy, and neuroinflammation. Additional studies involving animal models of AD indicate that some AD-related genotypic determinants may be critical factors enhancing temporal and phenotypic symptoms of TBI. Thus in the present study, we examined sub-acute effects of moderate TBI delivered by a gas-driven shock tube device in Aβ depositing Tg2576 mice. Three days later, significant increases in b-amyloid deposition, glycogen synthase-3 (GSK-3) activation, phospho-tau, and pro-inflammatory cytokines were observed. Importantly, peripheral treatment with the naturally occurring flavonoid, luteolin, significantly abolished these accelerated pathologies. This study lays the groundwork for a safe and natural compound that could prevent or treat TBI with minimal or no deleterious side effects in combat personnel and others at risk or who have experienced TBI.
- 9 January 2014
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 15 (1) , 895-904
Open AccessLuteolin Reduces Alzheimer’s Disease Pathologies Induced by Traumatic Brain Injury
Traumatic brain injury (TBI) occurs in response to an acute insult to the head and is recognized as a major risk factor for Alzheimer’s disease (AD). Indeed, recent studies have suggested a pathological overlap between TBI and AD, with both conditions exhibiting amyloid-beta (Aβ) deposits, tauopathy, and neuroinflammation. Additional studies involving animal models of AD indicate that some AD-related genotypic determinants may be critical factors enhancing temporal and phenotypic symptoms of TBI. Thus in the present study, we examined sub-acute effects of moderate TBI delivered by a gas-driven shock tube device in Aβ depositing Tg2576 mice. Three days later, significant increases in b-amyloid deposition, glycogen synthase-3 (GSK-3) activation, phospho-tau, and pro-inflammatory cytokines were observed. Importantly, peripheral treatment with the naturally occurring flavonoid, luteolin, significantly abolished these accelerated pathologies. This study lays the groundwork for a safe and natural compound that could prevent or treat TBI with minimal or no deleterious side effects in combat personnel and others at risk or who have experienced TBI.